Cochlear Ltd (Cochlear) manufactures and markets implantable hearing devices for patients suffering from hearing loss and develops integrated hearing solutions. Its major products include cochlear implant systems for patients with moderate to profound sensorineural hearing loss; bone conduction systems for patients with conductive hearing loss, mixed hearing loss, or single-sided deafness; and acoustic implants for patients with moderate to severe sensorineural or mixed hearing loss.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cochlear accelerated its long-term innovation pipeline through major R&D initiatives, including the commercial launch of the smart Nucleus Nexa System, the commencement of pivotal clinical studies for a totally implantable cochlear implant, and advancements in its drug-eluting electrode program. The R&D units of the company are located across primary hubs in Sydney (Australia), Belgium, Sweden, France, and Malaysia. The R&D units are responsible for maintaining a global innovation network and managing the company's R&D activities. The company has over 600 R&D professionals, a portfolio of more than 2,300 patents and applications, and is involved in major R&D initiatives. In FY2026, the company spent AUD323.2 million on its R&D activities, which as a percentage of revenue stood at 13.8% and grew 10.9% YoY.